<DOC>
	<DOCNO>NCT02757963</DOCNO>
	<brief_summary>This non-randomized , interventional study conduct general practice set assess utility benign prostatic enlargement ( BPE ) /benign prostatic obstruction ( BPO ) screen tool conjunction prostate specific antigen ( PSA ) find men confirm BPH full urologist assessment diagnostic test result . The tool may help General Practitioners ( GP ) identify subject may BPH test improve speed referral specialist appropriate . The utility screen tool compare validated tool wide clinical use , International Prostate Symptom Score ( IPSS ) . This study formal hypothesis term primary secondary endpoint proportion . A BPE/BPO screen tool identifies low urinary tract symptom ( LUTS ) probably due BPH men yet present LUTS . The result screen tool use investigation . All subject test positive BPE/BPO screen tool ( score &gt; =3 ) tool IPSS ( score &gt; =8 ) enrol offer PSA test urinalysis establish diagnosis probable BPH ( Part I-Visit 1 ) . The GP may perform digital rectal examination ( DRE ) repeat urologist confirm diagnosis rule abnormality suggest prostate cancer . The GP make diagnosis probable BPH base upon screen result lab test suggest relate BPH cause symptom . The GP phone subject report yes probable BPH Part II ( Visit 2 ) . If subject probable BPH , GP schedule subject Visit 3 urologist . If subject probable BPH , consider subject complete study . Subjects proceed Part II ( Visit 3 ) schedule urology assessment perform urologist . This assessment include DRE brief physical exam review PSA test , confirmatory diagnosis BPH estimation risk progression BPH . Approximately 1,500 subject present GP reason unrelated study screen probable BPH yield 500 subject refer urologist . The duration study 1 week ( +/- 4 day ) 6 week allow GP urologist visit scheduling .</brief_summary>
	<brief_title>Benign Prostatic Hyperplasia ( BPH ) Screening Tool Case Finding Study Subjects &gt; =50 Years</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Greater equal ( &gt; = ) 50 year age time sign informed consent form . Male . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Present General Practice set reason unrelated study . Positive IPSS score &gt; =8 and/or positive BPE/BPO screen tool score &gt; =3 . History BPH receive test procedure , medical intervention and/or medicine . History prostaterelated LUTS receive test procedure , medical intervention and/or medicine . History prostatic surgery ( include transurethral resection prostate ( TURP ) , balloon dilatation , thermotherapy , and/or stent replacement ) invasive minimally invasive procedure treat BPH . Has condition may cause urinary symptom ( e.g. , neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute chronic prostatitis , acute chronic urinary tract infection , etc. ) . History evidence prostate cancer ( e.g. , positive biopsy ultrasound , suspicious DRE and/or rise PSA ) . Current prior use following : 5alphareductase inhibitor ( finasteride dutasteride ) ; anticholinergic ( e.g . oxybutynin , propantheline , tolterodine , solifenacin , darifenacin , mirabegron ) alphaadrenoreceptor blocker ( i.e. , indoramin , prazosin , terazosin , tamsulosin , alfuzosin , doxazosin silodosin ) , herbal product urinary symptom ; Use investigational study drug within 30 day 5 halflives drug question , ( whichever longer ) , precede first study visit . Use within previous 30 day Visit 1 : phosphodiesterase type 5 inhibitor ( PDE5 ) inhibitor erectile dysfunction ; anabolic steroid</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Screening tool</keyword>
	<keyword>International Prostate Symptom Score</keyword>
	<keyword>Lower urinary tract symptom</keyword>
	<keyword>BPO</keyword>
	<keyword>BPE</keyword>
	<keyword>Benign prostatic enlargement</keyword>
	<keyword>Benign prostatic obstruction</keyword>
	<keyword>LUTS</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>IPSS</keyword>
	<keyword>BPH</keyword>
</DOC>